KEYNOTE-921

Trial description
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)
Contact name
Dr Danish Mazhar
Trial start date
Tuesday, September 24, 2019
Trial end date
Thursday, April 30, 2020
Trial tumour type
Prostate
Show on Radiotherapy
No